PNTG vs. SHC, PRVA, CON, SGRY, ADUS, VCYT, PACS, WGS, LFST, and ARDT
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include Sotera Health (SHC), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Addus HomeCare (ADUS), Veracyte (VCYT), PACS Group (PACS), GeneDx (WGS), LifeStance Health Group (LFST), and Ardent Health (ARDT). These companies are all part of the "healthcare" industry.
The Pennant Group vs. Its Competitors
Sotera Health (NASDAQ:SHC) and The Pennant Group (NASDAQ:PNTG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
The Pennant Group has a net margin of 3.40% compared to Sotera Health's net margin of 2.24%. Sotera Health's return on equity of 41.08% beat The Pennant Group's return on equity.
In the previous week, The Pennant Group had 3 more articles in the media than Sotera Health. MarketBeat recorded 5 mentions for The Pennant Group and 2 mentions for Sotera Health. The Pennant Group's average media sentiment score of 0.81 beat Sotera Health's score of 0.34 indicating that The Pennant Group is being referred to more favorably in the news media.
Sotera Health has higher revenue and earnings than The Pennant Group. The Pennant Group is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
91.0% of Sotera Health shares are held by institutional investors. Comparatively, 85.9% of The Pennant Group shares are held by institutional investors. 47.6% of Sotera Health shares are held by insiders. Comparatively, 5.4% of The Pennant Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Sotera Health currently has a consensus target price of $16.00, suggesting a potential upside of 36.23%. The Pennant Group has a consensus target price of $34.60, suggesting a potential upside of 31.58%. Given Sotera Health's stronger consensus rating and higher probable upside, analysts plainly believe Sotera Health is more favorable than The Pennant Group.
Sotera Health has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
Summary
Sotera Health beats The Pennant Group on 12 of the 16 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
This page (NASDAQ:PNTG) was last updated on 7/6/2025 by MarketBeat.com Staff
Free PNTG Stock Alerts